Examples of using Open-label in English and their translations into Finnish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
In CHARM, 854 patients received open-label 80 mg at week 0
Abatacept was also evaluated in an open-label study in rheumatoid arthritis patients administered the seasonal influenza trivalent virus vaccine.
Preliminary results from a supportive study(Study ELT116826), an ongoing non-randomised, phase II, single-arm, open-label study in refractory SAA subjects.
In an open-label clinical study(ACTG 180)
controlled, open-label Phase III clinical study(FLAGS)
In the pre-antiviral treatment phase, subjects received open-label eltrombopag to increase the platelet count to≥ 90,000/µl for ENABLE 1 and≥ 100,000/µl for ENABLE 2.
The MAH should conduct a multicentre, randomized, open-label, Phase 2a study of Strensiq in patients with hypophosphatasia(HPP) to.
The safety profile in a 26-week open-label extension trial was similar to that observed in the short- term, placebo-controlled trial.
if the response was not maintained during the open-label treatment period,
This study was an open-label, randomised, active-controlled(sevelamer carbonate),
In an open-label clinical trial(ACTG 180)
Actelion will conduct an open-label study to provide safety
Study 02607 was a randomized, open-label, active-controlled, non-inferiority,
Two long-term, open-label, flexible-dose studies demonstrated that serum phosphorus reduction was maintained for up to one year.
In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.
PASI 75 and PGA of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an additional 108 weeks of open-label therapy total of 160 weeks.
controlled, open-label study in which 173 subjects with previously treated CLL received idelalisib+ ofatumumab.
Two similar 12-week, open-label, flexible-dose studies followed by a 4-week double-blind withdrawal period(comparison to placebo) were performed.
pharmacokinetics of Genvoya were evaluated in an open-label study in HIV-1-infected, treatment-naïve adolescents.
Study PR-011 was an open-label crossover study in 15 patients,